retrospective analysis of routinely collected data from 8724 cardiac surgical patients that the number of red cell units transfused is an independent risk factor for a poorer outcome including mortality. In addition to dose-related effects, in a further retrospective study of cardiac surgical patients in 2008, Koch and colleagues compared 2872 patients who received red cells that were ,14 days old with 3130 patients who received red cells that were .14 days old. Despite adjusting for key confounding variables, including patient factors and operative details, they found a significantly increased risk of postoperative complications and a reduction in short-and long-term survival associated with the transfusion of older red cells. 3 The pathophysiology of these findings may be related to structural and functional changes in red cells during storage and is detailed in Table 1 . Leucocytes transfused with red cells may also be implicated in the adverse effects of older blood; however, this effect is likely to have been mitigated in the UK by the introduction of leucodepletion in 1999.
Furthermore, blood transfusion undoubtedly has an immunomodulatory effect upon the recipient (Table 1) which may be associated with better outcomes after renal, cardiac, and liver transplantation, but worse outcomes in cancer recurrence, perioperative infection, and metastasis.
Transfusion-associated circulatory overload
Transfusion-associated circulatory overload (TACO) is characterized by acute respiratory distress, tachycardia, relative hypertension, raised central venous pressure, natriuretic pulmonary oedema, and positive fluid balance. It occurs usually within 6 h, but upto 24 h of transfusion.
The chest X-ray shows interstitial oedema, possibly in association with cardiomegaly, reflecting the underlying pathophysiology of acute heart failure; and a post-transfusion to pre-transfusion brain natriuretic peptide ratio of .1.5, if available, is diagnostic. TACO may occur either during massive transfusion or during too rapid transfusion, and it is likely that this is an extremely under-reported complication.
TACO is entirely avoidable and a thorough pretransfusion assessment for cardiac failure, renal impairment, hypoalbuminaemia, or pre-existing fluid overload should always be undertaken. Children are particularly at risk, especially if the product is prescribed in units rather than millilitres per kilogram. The use of 'paedipacks' where a
Key points
Blood transfusion may be life saving, restoring the circulating volume and oxygen delivery in haemorrhage, and controlling the symptoms of anaemia.
The clinician must be aware of the hazards and complications associated with blood transfusion and how to effectively manage them if they occur.
Blood transfusion is proportionally associated with more risk in children than in adults.
Inappropriate or unnecessary transfusion remains common.
Current evidence suggests that restrictive, haemoglobin-based transfusion strategies may be appropriate in the majority of patients and contribute to improved transfusion safety.
unit of red cells is split into several smaller volume aliquots has helped to reduce this risk. It is essential to monitor the rate of transfusion, arterial pressure, arterial oxygen saturation, respiratory rate, and ongoing fluid balance in all patients receiving a blood product. Treatment of TACO is detailed in Table 3 .
Transfusion-related acute lung injury
Transfusion-related acute lung injury (TRALI) is defined as a new acute lung injury characterized by non-cardiogenic pulmonary oedema occurring within 6 h of transfusion. The pathophysiology is detailed in Table 1 ; of note, fresh frozen plasma (FFP) is associated with the highest incidence of immune-mediated TRALI.
Principal features of TRALI include dyspnoea, hypotension, pulmonary oedema (without evidence of left ventricular failure), and fever. Differential diagnoses include TACO, with which it can co-exist, and other causes of acute lung injury. TRALI was a leading cause of transfusion-related mortality; however, this has decreased radically since the introduction of the risk reduction strategies listed in Table 2 .
Treatment of TRALI is supportive (Table 3 ) and the acute lung injury usually resolves quickly, with the disappearance of pulmonary infiltrates within 96 h.
Haemolytic transfusion reactions and alloimmunization
The classification of blood groups is based upon the presence of different oligosaccharide antigens (agglutinogens) present on red cell membranes and agglutinins present in the plasma. There are 29 agglutinogen-agglutinin systems; however, most haemolytic transfusion reactions involve the ABO and Rhesus (Rh) systems. Other common groups include Duffy, Kidd, and Kell.
In the ABO system, Type A individuals have circulating plasma anti-B antibodies, Type B have anti-A antibodies, Type O has both, and Type AB has neither. Transfusion of incompatible red blood cells against which the recipient has antibodies results in inflammation, increased vascular permeability and hypotension. Intravascular haemolysis may occur leading to disseminated intravascular coagulation (DIC), renal failure, and death.
Haemolytic transfusion reactions may be immediate (acute), or delayed. Acute reactions occur within 24 h and can be confirmed by a reduction in haemoglobin, an increase in lactate dehydrogenase, a positive direct antiglobulin (Coomb's) test, or a positive cross match test. The symptoms, signs, and treatment are detailed in Table 3 .
Delayed haemolytic reactions generally occur 3 -10 days after transfusion. In these, the recipient is already alloimmunized to minor alloantibodies (e.g. the Rh or Kidd systems, from a previous transfusion or pregnancy). The concentration of these alloantibodies is usually low and, therefore, not detected on pre-transfusion screening. They respond to the re-presentation of antigen positive red blood cells, leading to degranulation of mast cells and haemolysis. The signs include a reduction in haemoglobin, fever, and rarely haemoglobinuria or renal failure. Possible bradykinin release leading to vasodilatation and increased vascular permeability TAD Unknown Post-transfusion purpura A previously sensitized recipient produces alloantibodies which attack donor platelet antigens and also destroy their own platelets Transfusion-associated graft vs host disease Lymphocytes from the donor proliferate within an immunocompromised recipient, or an immune competent recipient who has a very similar HLA type to the donor (e.g. a first degree relative) Transfusion-related iron overload Circulating iron from recurrent transfusions exceeds the binding capacity of transferrin and becomes deposited in organs including the heart and the liver. Here, it causes free-radical formation and generation of lipid peroxidation products resulting in progressive tissue injury, cirrhosis, and cardiomyopathy
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Continuing Importantly, anti-D antibodies are small enough to cross the placenta. Haemolytic disease of the newborn occurs if an Rh-negative mother has an Rh-positive fetus during her first pregnancy. She may develop anti-D antibodies which cross the placenta and attack a second Rh-positive fetus, resulting in haemolytic disease of the newborn with anaemia, jaundice, heart failure, and even stillbirth.
This may be prevented by giving an Rh negative mother carrying an Rh positive fetus anti-D immunoglobulin at 30 weeks' gestation and during the postpartum period. This destroys any fetal Rh-D-positive blood cells in the maternal circulation before the immune system can produce antibodies.
Acute transfusion reactions
Acute transfusion reactions are defined as any reaction occurring within 24 h of a transfusion excluding TACO, TRALI, or haemolytic transfusion reactions. They are classified by the British Committee for Standards in Haematology (BCSH) as febrile, allergic, those with features of both, and reactions characterized solely by hypotension. They may range in severity from mild to severe.
Non-haemolytic febrile transfusion reactions
Non-haemolytic febrile transfusion reactions are very common; if symptoms are mild, they require little intervention. An increase of 28C is diagnostic if other causes of pyrexia (e.g. sepsis and haemolysis are excluded). Usually, treatment is not required other than oral paracetamol; however, severe reactions may be associated with rigours, myalgia, nausea, and hypotension and may prompt discontinuation of the transfusion.
Allergic transfusion reactions
Mild allergic reactions cause transient flushing or urticaria. The incidence of allergic reactions has not altered since the introduction of Hazards of blood transfusion leucodepletion, suggesting that the likely pathophysiology relates to soluble antigens within the donor unit in an already sensitized recipient, rather than cytokines released from donor white blood cells.
Most severe allergic transfusion reactions may cause wheeze or angioedema but are typically without significant respiratory compromise or hypotension. Conversely, anaphylaxis, the most severe allergic reaction, may be life threatening and occurs in 1:20 000-50 000 transfusions.
As there is always a small risk of anaphylaxis during transfusion, the UK resuscitation council guidelines mandate that transfusion should only be undertaken where there are facilities to recognize and treat anaphylaxis if it occurs.
Combined features of both febrile and allergic reactions Some transfusion reactions have both febrile and allergic features with both leucocyte and soluble antigen based reactions.
Hypotensive reactions
Some transfusion reactions are characterized solely by a decrease in systolic or diastolic arterial pressure of at least 30 mm Hg in the absence of anaphylactic or allergic symptoms. Treatment includes the administration of oxygen and fluids as required; this reaction may be more common in patients taking angiotensin converting enzyme inhibitors.
Transfusion-associated dyspnoea
Transfusion-associated dyspnoea (TAD) is characterized by respiratory distress within 24 h of transfusion which does not meet the criteria of an allergic reaction, TRALI, or TACO. All patients who develop any form of respiratory distress after transfusion should receive supplemental oxygen and respiratory rate, haemodynamic, and oxygen saturation monitoring.
Post-transfusion purpura
Post-transfusion purpura is rare. It is more common in highly multiparous females because of prior sensitization, and generally occurs 5-10 days after transfusion resulting in severe thrombocytopaenia (,10Â10 9 l in 80% of cases), purpura, and bleeding from mucosal membranes. It is usually self-limiting; however, it may be fatal and if treatment is required, steroids, i.v. immunoglobulin G, or plasmapheresis may be effective.
Transfusion-associated graft vs host disease
Transfusion-associated graft vs host disease (TA-GVHD) has an almost 100% mortality; fortunately, it is very rare with no reported cases in the UK since 2001. The pathophysiology is detailed in Table 1 and symptoms occur within 30 days of transfusion including fever, rash, liver dysfunction, diarrhoea, pancytopaenia, and bone marrow hyperplasia. Diagnosis is by skin or bone marrow biopsy and the identification of donor-derived cells, chromosomes, and DNA in the patient's blood or tissues. Prevention of TA-GVHD includes leucodepletion plus gamma irradiation of blood products before transfusion leaving the few remaining donor lymphocytes unable to proliferate in the recipient. Susceptible patients include those with congenital T-cell 
Transfusion-related iron overload (haemosiderosis)
Each unit of red blood cells contains 250 mg of iron. As the body has no effective mechanism for excreting iron other than by blood loss, patients receiving recurrent transfusions (e.g. those with sickle cell disease, beta thalassaemia, or myelodysplasia) are at risk of iron accumulation with deposition in the liver, heart, pancreas, and endocrine organs. This ultimately leads to cirrhosis, cardiomyopathy, diabetes, arthritis, and testicular failure. The use of recurrent venesection or iron chelation therapy with deferoxamine may delay or prevent the onset of iron overload in susceptible patients.
Transfusion transmitted infection
Transfusion transmitted infection (TTI) is an increasingly uncommon, but ever-present, hazard of transfusion. Donor selection guidelines exclude high-risk populations such as i.v. drug users from the donor pool. In addition, donated blood is routinely screened for a variety of viruses, syphilis, and in those with a travel history that puts them at risk of malaria, trypanosome cruzi, or West Nile virus.
Bacterial contamination
Bacterial contamination represents the greatest risk for the recipient; the major bacterial contaminants are skin organisms acquired at the time of donation. Improved donor arm disinfection with chlorhexidine in alcohol and discarding the initial flow of blood before it enters the collection bag have been highly effective in reducing bacterial contamination.
Platelets have the highest risk of bacterial contamination (1:2000) because they are stored at room temperature; the risk with red cell concentrates is much lower at 1:500 000. 4 All blood components should be examined for clumps, discolouration, and damage to the bag before administration.
Viral contamination
Viral contamination of blood is now extremely rare because of leucodepletion, the suspension of red cells in minimal amounts of plasma, and careful donor selection. Donated blood is routinely screened for human immunodeficiency virus (HIV), hepatitis B and C, and human T cell lymphoma virus 1. Leucodepletion has greatly reduced the transmission of cytomegalovirus (CMV); however, blood is still screened for specific vulnerable groups of recipients such as fetuses, neonates, and pregnant women receiving elective transfusions.
Variant Creutzfeld Jacob disease
In the 1990s, the UK population was exposed to the prion disease bovine spongiform encephalopathy (BSE) by contamination of the food chain. The infective prion protein was highly resistant to conventional sterilization, and transmissible by oral ingestion and transfusion. Transmission of prions was shown to be causally related to the development of variant Creutzfeld Jacob disease (vCJD), a degenerative neurological condition characterized by rapid onset dementia with speech, coordination, and gait disturbances. Lymphatic involvement is widespread, and survival typically limited to 6-24 months. Four probable cases of transmission have been reported after transfusion of red cells from asymptomatic donors who subsequently died of vCJD. In addition, there has been one case of likely transmission via UK Factor VIII concentrate produced from pooled plasma when one of the donors subsequently died from vCJD. All definite cases of vCJD have occurred in individuals within a genetic subset homozygous for methionine rather than valine at codon 129 of the prion protein gene. It is uncertain at this stage whether this disease will occur in other genetic subgroups. Continuing surveillance of vCJD in the UK and other countries in which BSE has been identified is essential for future global estimations of disease prevalence. It is entirely possible that there are healthy carriers within the population, and at present, there is no widely available diagnostic test or effective treatment for this disease.
Complications of massive transfusion
Massive transfusion is defined as the transfusion of 10 units of blood or the complete replacement of the circulating blood volume within 24 h.
Hypothermia
Red blood cells are stored at 48C; hypothermia is therefore a common complication of massive transfusion. Trauma and surgical patients are at particular risk because of exposure, open body cavities, decreased heat production, and impaired thermoregulation.
Mild hypothermia (.338C) is well tolerated and has clear benefits, particularly after cardiac arrest. More severe hypothermia, however, may lead to peripheral vasoconstriction, metabolic acidosis, cardiac dysfunction, decreased citrate metabolism, decreased drug clearance and synthesis of acute phase proteins, reduced tissue oxygen delivery by shifting the Bohr curve to the left, and infection. Platelet function is also impaired, and each reduction of 18C is associated with a 10% reduction in coagulation factor activity.
Coagulopathy
A dilutional coagulopathy may occur during major haemorrhage because of inadequate replacement of clotting factors and platelets. Post-traumatic coagulopathy may be additionally related to injury severity, fibrinolysis, hypothermia, hypocalcaemia, acidosis, and platelet consumption. Crush injuries, obstetric complications,
Hazards of blood transfusion
and sepsis can cause DIC resulting in activation of the coagulation and fibrinolytic systems, further consuming platelets, clotting factors, and fibrinogen.
Thus, the haemodilution of massive transfusion and the coagulopathy of massive haemorrhage may potentiate one another, further increasing morbidity and mortality.
Acid -base disturbance
Red blood cells suspended in both citrate-phosphate-dextroseadenine solution and saline-adenine-glucose-mannitol have a pH of 7.2, which decreases to 6.4 after 21 days of storage. As cellular metabolism is essentially anaerobic, the concentration of lactic acid also rises during storage providing on average 1 -2 mmol unit 21 of red cells. 5 Despite this, the acidosis associated with massive transfusion is more usually attributable to incomplete resuscitation and persisting tissue hypoperfusion rather than the acidity of the product transfused.
Electrolyte abnormalities
With increasing storage times the active uptake of potassium into red cells decreases; thus, a unit of red cells stored for 4-5 weeks may contain 5 -30 mmol litre 21 of extracellular potassium. The infusion of such a unit may cause cardiac arrhythmias in susceptible patients such as neonates and those with renal failure or major tissue injury. After transfusion, as active metabolism recommences, potassium is taken up into the cells. This may result in hypokalaemia when combined with the release of aldosterone, antidiuretic hormone, and catecholamines in response to stress. Concomitant platelets and FFP transfusion are also low in potassium and large volumes can further contribute to hypokalaemia. FFP and platelets are stored in sodium citrate, designed to bind calcium, and prevent coagulation during storage. The citrate is normally metabolized by the liver; however, patients receiving a massive transfusion or those with impaired liver function or hypoperfusion are at risk of citrate accumulation with active binding of circulating calcium and magnesium resulting in hypocalcaemia and hypomagnesaemia.
System failure and human factors
Approximately half of the adverse events related to blood transfusion reported in 2011 were attributable to human error. For every incorrect blood component transfused, there were 100 near misses. Proportionally, there are more adverse events reported in children than in adults, the risk increasing with decreasing age. In particular, the incidence of incorrect blood component transfused is twice as common in children, predominantly attributable to the failure of effective identity checks before transfusion, and also perhaps because transfusion is less common in paediatrics and staff may be less familiar with the associated hazards. Neonates are particularly at risk as they may not yet be named, several babies may share the same birthdates, and their parents may not always be present to confirm their identity. Similarly, anaesthetized patients are at high risk as they are unable to confirm their details and access to identity bracelets can be difficult in theatre.
Inappropriate, unnecessary and under/delayed transfusions
Inappropriate, unnecessary, delayed, or inadequate transfusions are also common and probably under-reported. Many of these transfusion errors are based on erroneous results (e.g. from blood obtained from a drip arm, poorly calibrated point-of-care testing analysers, or miscommunication) and could have been avoided if a second sample had been requested when the first result was suspected to be inaccurate.
Regulation, audit and oversight
In order to minimize the hazards associated with transfusion described above, the Blood Safety and Quality Regulations were enshrined in UK criminal law in 2006. This legislation controls all aspects of transfusion in the UK, including full traceability of all blood component transfusions for 30 yr. 6 The Medicines and Healthcare products Regulatory Agency ensures compliance with these regulations and mandates that that all serious adverse reactions to blood transfusions are reported to them via the Serious Adverse Blood Reactions and Events system (SABRE). Also, the Serious Hazards of Transfusion (SHOT) haemovigilance system, which has now reported for 15 yr, represents a voluntary confidential reporting system for near misses and serious adverse events occurring in the laboratory or clinical environment.
Further, death or serious harm as a result of inadvertent transfusion of ABO-incompatible blood components is classified as a Never Event by the Department of Health 7 (a serious, preventable patient safety incident that should not occur if the available measures had been implemented). This triggers significant penalties against the Trust in which it occurred.
Strategies to minimize the risks associated with transfusion
The process of transfusion, from identifying possible donors to the final administration of the correct component to the correct patient, is complicated and it is vital that all individuals involved in transfusion engage with systems designed to minimize the numerous potential hazards. These strategies include education regarding the risks and training in proper techniques for sampling, preparation, storage, issuing, checking, and administering blood components. The BCSH produces regularly updated guidelines addressing all aspects of transfusion providing a valuable resource for clinicians working in this area.
this precious resource intelligently with a clear understanding of the potential risks and an understanding of the aims of therapy including the use of an appropriate transfusion trigger. In particular, children are at high risk of transfusion-related adverse events and the possible long-term effects of transfusion must be carefully weighed against the benefits. In this context, a restrictive transfusion strategy may be associated with fewer adverse events and a better outcome than the now historic more liberal approach. 8 In order to improve global transfusion practice, the World Health Organization has adopted the principles of Patient Blood Management, which combines the treatment of preoperative anaemia, reduction of perioperative blood loss, and the use of restrictive haemoglobin-based transfusion triggers to continue to refine and improve transfusion safety.
